S&P Futures
5,904.50 -1.50 (-0.03%) Dow Futures
43,540.00 +22.00 (+0.05%) Nasdaq Futures
20,461.25 -22.25 (-0.11%) Russell 2000 Futures
2,292.90 +1.70 (+0.07%) Crude Oil
69.67 +0.45 (+0.65%) Gold
2,743.60 +13.60 (+0.50%)
Pharmala Biotech Holdings Inc. (MDXXF)
- GlobeNewswire
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a proposed clinical trial at the University of Texas, San Antonio. Pursuant to a submitted grant funding application by the principals, the contrac
- GlobeNewswire
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a clinical trial at Harvard’s Maclean Hospital, the largest neuroscientific and psychiatric private research hospital in the world. “As has recently
